Great Lakes Advisors LLC Sells 8,124 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Great Lakes Advisors LLC cut its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 4.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 191,129 shares of the biopharmaceutical company's stock after selling 8,124 shares during the quarter. Great Lakes Advisors LLC owned 0.21% of Ultragenyx Pharmaceutical worth $8,041,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the stock. Alkeon Capital Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 34.3% during the third quarter. Alkeon Capital Management LLC now owns 3,011,716 shares of the biopharmaceutical company's stock worth $167,301,000 after buying an additional 769,884 shares in the last quarter. Baker BROS. Advisors LP increased its stake in shares of Ultragenyx Pharmaceutical by 7.5% in the third quarter. Baker BROS. Advisors LP now owns 1,576,114 shares of the biopharmaceutical company's stock valued at $87,553,000 after buying an additional 109,567 shares during the period. Geode Capital Management LLC grew its holdings in Ultragenyx Pharmaceutical by 4.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,571,081 shares of the biopharmaceutical company's stock worth $87,296,000 after acquiring an additional 65,623 shares during the period. Two Sigma Advisers LP grew its position in shares of Ultragenyx Pharmaceutical by 123.4% during the 3rd quarter. Two Sigma Advisers LP now owns 987,800 shares of the biopharmaceutical company's stock worth $54,872,000 after buying an additional 545,600 shares during the period. Finally, Point72 Asset Management L.P. boosted its position in shares of Ultragenyx Pharmaceutical by 35.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 653,660 shares of the biopharmaceutical company's stock worth $36,311,000 after purchasing an additional 172,711 shares in the last quarter. Institutional investors own 97.67% of the company's stock.

Remove Ads

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ RARE traded up $0.09 during mid-day trading on Friday, hitting $39.34. The stock had a trading volume of 401,537 shares, compared to its average volume of 780,638. Ultragenyx Pharmaceutical Inc. has a 1 year low of $36.87 and a 1 year high of $60.37. The business has a 50 day moving average price of $42.33 and a two-hundred day moving average price of $48.25. The firm has a market cap of $3.64 billion, a P/E ratio of -6.21 and a beta of 0.67.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.32) by ($0.07). The firm had revenue of $164.88 million for the quarter, compared to the consensus estimate of $163.23 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. Equities research analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, insider John Richard Pinion sold 14,439 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $607,881.90. Following the completion of the sale, the insider now directly owns 107,766 shares in the company, valued at $4,536,948.60. The trade was a 11.82 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Theodore Alan Huizenga sold 967 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $40,710.70. Following the sale, the chief accounting officer now directly owns 50,265 shares of the company's stock, valued at $2,116,156.50. This represents a 1.89 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 136,370 shares of company stock worth $5,751,499. 5.80% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Canaccord Genuity Group lifted their price target on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research report on Tuesday, February 18th. Piper Sandler increased their price objective on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an "overweight" rating in a research note on Monday, January 13th. Cantor Fitzgerald reiterated an "overweight" rating and set a $118.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. Wells Fargo & Company raised their price objective on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an "overweight" rating in a research note on Friday, December 20th. Finally, HC Wainwright reiterated a "buy" rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $93.50.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.